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~ Pnlvnlstln Art!vat~ Endothelial Nitric Ox!d~ 
Synthatm Independent of Ht Lipid Lowering A¢llons 
WH. Kaesemeye~, RB Cafdwel!, T.A, Taylor, J, Huang~ RW. Caldw~lL 
Oepa~t  ot Pt~rmaco~gy ~ T~og) ,  a~l Vascular B~otogy Center, 
Medrat College ot Ge~qpa, Aug;.~ta, GA 30912, USA 
~gm~-  Recent sfudms with pravastat~n (PRA) have suggested that 
mduclto~s in n~,ora~! infarction and strok~ ate not totslly explained by 
reductions in LDL chek~ferol (LDL¥ A study comparing the effects of PRA 
~,,s, Simvastalin s ~  that only PRA lnh~b~led platelel aggmgatm~ with no 
ddference in actions ~t~,en  the agents on chotasteroI levels. Since ntmc 
osick~ (NO) is a welt known inh~b~to¢ f platetet aggregatmn, we investigated 
the poss=b~hty hat PRA =s an agonmt of enc!othelial mtnc ox~ synthase 
(eNOS) l~n~nt  0t its lipid towem'~ ac~or~. 
Methods." NO pmdect~ was measured by convem~n of hemogfol~n to 
n'm~n'~g~cb~ and by use of a NO sensd.~e leci~rode using isolated bo~ne 
aodic endothelial cedis in c~Jm. Resp~o.~--3 to ecety~choline (ACH) and 
PFIA for 3 rmn were measured in the presence and absence of nitro-L-ARG 
methyl ester (L-NAME, t0 3 M) and 11~en excess L-ARG ( t0  3 M)= 
Results: ACH and PRA (both at 10 ~ and 10 s M) stimulated NO l~mduc- 
hen to 227 & 521 and 185 & 413 nmoles min, respect~ely. L.NAME reduced 
these responses to 39 & 56 and 30 & 42% el roitial values, respect~,,e~y. Ex- 
cess L-ARG increased NO Wodt.'c~on to 134 & 149 and 123 & 133% of initial 
values, r~ ly .  These results were confirmed by NO measurements 
obtained troth an NO electrode. 
ConcluSion PRA can st;mutate eNOS a~[vtty Cl~n¢cat results seen w~th 
PRA not totally e~plamed by LDL reductions may be the result of an rode- 
pendent action of PRA on eNOS acbvabon 
1 0 :45  
8 - -0 -~ irect Demonstrat ion of  Nitric Oxide Formation 
From Purified Nitric Ox ide Synthase 
Y X~a, J L Zwe~er Johns Hopkins Unrvers~. ~chool of P, fe~ltc~ne. Battm'~re 
MD. USA 
Although nitno omde (NO). a central mediator of card=ovasoulaJ regulatron. 
iS ~dely considered to be denved from NO synthase (NOS), direct demon- 
straiten ot NO formation from the punfied enzyme has been lacking. Based 
on failure to detect NO from isolated NO~. it was recently reported that NOS 
does not synthesize NO. but rather generates nitroxyl anion (NO)  or nitrous 
oxide (Schmidt et at. PNAS 1996; 93: 14492). ~ proposed that NO is de- 
nved from NO in a reaction catalyzed by sup~roxide d~smutase (SOD). To 
determine if NOS synthesizes NO, electron paramagnettc resonance (EPR) 
spectroscopy was applied to directly measure NO formation from purified 
neuronal NOS. In the presence ot the NO trap Fe ~*-N-methyt-D-glucamine 
d=thiecarbamate. NO gives nse to a characteristic triplet EPR spectrum, with 
g = 2.04 and a~ = t2,7 G, whereas NO is undetectabfe. In the pres- 
ence of L-arginine (L-Arg) and cotactors. NOS generated prominent NO 
signals. In contrast to prewous observations. NO generation did not require 
SOD NO formation was blocked by the either the specific NOS inhibitor 
N-nitro-L-arginine methyl ester or by excluding NOS substr~te L-Arg. Iso- 
tope-labeling expenments with ~SN L-Arg demonstrated that NOS-catatyzed 
NO arose from the guanidino N of L-Arg. Analysis of the time course of 
NO formation revealed that it paralleled that Of the co-product L-citrulline as 
measured from the conversion of L-[~4C]Arg to L-[~4C]citrulline. Using the 
oxygen radical trap DMPO. potent superexide generation was observed in 
the reaction system used before. This superoxide was mainly derived from 
the reaction of NADPH with free FAD and may account for the prior failure 
to detect NO. Together, these experiments provide the demonstration that 
punfied NOS does directly synthesize NO. 
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~ Tissu~ Fitter Pathway Inhibitor t~lestw Is SlNDCttl¢ 
.for Heputln a.ml Low Molecular Weight Hepnt|ne, 
I mpl.t~.lon= In the Mlnllglm-~nt o! Coronary 
wmrome~ 
D, H0ppensteadt, ,i: FaJreed, J, AmiraP, W, Jeske, JM  Wa~,  B, Lewis, 
O, WeL~el ~, Loyo~ Un~er~#y Medcal Cenfer, M ~ ,  IL, USA; ~Sed~ 
Gennevdlers, France: ~ Frec~¢k Lcetler Sfr~;se~ Nurnberg~ Germany 
P l~ I1jpture resulting in the r~03se Of 011 §~ fi~SO~ f~1or (TF) represents 
a Pw0Ia! event in COronary .ptclromes Basal level~ of fetal and tre~ tissue 
factor pathway inhibitor (TFPI) are strongly influenceO by hepanni;~afion a d 
a (:fo~ dependent ~'rease is ob~fved aller both the IV and SC admin. 
Istrat~on o| hepanrm. Plasma ~mple~ ~o~lected from patients treated with 
hepad~l/Iow molecular werght hepanns (LMW~s) and antithromb~n drugs 
(lllrudtn and argatrob~ln) from vanouS ctLn~al lnats (PTCA, thrombolys!s, 
unstable angina) were compared for the relative release of TFPI, Unfrac. 
tional~l hepann and LMWHs produced a dese and route dependent (3-10 
fold) iocrease in the folal and free TFPI (up fo 30 fold) (~a l  levels', free 
TFPI 92 ± 2.4; total TFPI 74.g ± 9.6, n ~ 250) in varmus studies. Recom- 
bina~ hirudm, hlrulog and argetmban at comparable anticoagulant levels 
in both therapeutic (APTT 70-100 sees.) and surg~al/lnlerventional (ACT 
400-600 secs_) protocols tmled to produce any si~t'tiflcant elevation of both 
forms ot TFPt. Additional analysis of these samples for markers of thromb|n 
generalmn auch a~ prothromhin fragment F 12 and thrombln antlthrombm 
complex also revealed that nepann and LMW~ patients have sige~ticantty 
lower lev,=?. LsO! these markers in COntrast o patients treated with antithrom~n 
agents (p < 001). Since TFPI represerds a spe~fic and potent modulator of 
TF the obsewed supenor efficacy o! bepattn m coronary syndromes may be 
attnbutsbte to their aclmns on the release of this inhibrtor. 
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[80-~ Hirudin (Desulfated, 54-65) Causes Contract ion of 
Canine Coronary  Arteries WhiCh Is Attenuated by 
Calcium-Channel Blockers 
Paul Soraiia. Da~d G. Cable, Hartzell V Schaff Ma~ Chn~c. Rochester, 
Minnesota. USA 
Background. Hirudln is a novel anhthrombin agent with potent antlcoagulaton/ 
properties P'evious st~hes have demonslrated that hirudwn (desuttated, 
54-65) stimulates the release ot nitric oxide in pormne pulmonary affenes. 
We inves~g~fed hmJd~n for its direct effect:= on COrOnary artenes. 
Methods and Rasults: Canine coronary adenes were mounted in organ 
chambers and precontracted with prostaglandin F2tr (2 ~ 10 6 M), In artenes 
with intact endothelium, hirudm (10 to to 10 s M) increased vascular tension 
336 ± 9.0% above baseline tension (n = 10, p :~ 0.05, ANOVA). Similarly, 
in adenes denuded of endothelium, htrudin increased vascular tension 318 
~- 11.2% above baseline ten.on (n = 8. p ~ 0.05). denlon~rsting that the 
hirudin-rnediated contractions were endothellum-independent Pretreatment 
of the corOnary arteries ~.lth either verapamil (10 4 M) or nifedipme (10 '= 
M) for one hour attenuated hirudin-mediated vascular contractmns. Whereas 
control arfedes contracted 26.4 ~ 103% above baseline tension, hinJdin 
administration i creased vascular tension 3.8 ~: 7.0% above baseline tansmn 
in artenes pretreated w;th verapamil (n = 6. P :~ 0.05 vs. contrOl) and 62 
± 12.4% above baseline tension in artenes pretreated w~lh nifedipine (n 
= 6. p ~ 0.05). Contractions to hirudin were also observed in artenes not 
precontacted with prostaglandin F2. (n : 3). suggesting that the resting 
tension of the coronary artery was not =mportant inhirudin-m~diated vascular 
responses. 
Conclusions: The t3resent study demonstrates that hirud~n induces en- 
dothelium-independent contractions of camne coronary artenes. Pretreat- 
merit with calcium-channel btockers attenuated these contractions, suggest- 
ing a possible mechanism ~extracetlular influx of calcium) by which bin.trim 
mediates coronary artery contsnction. 
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